Cyclacel pharmaceuticals announces agreement for the acquisition of preferred stock by david lazar

David lazar agrees to invest $3.1 million in preferred stock and becomes interim ceo david lazar agrees to invest $3.1 million in preferred stock and becomes interim ceo

CYCC Ratings Summary

CYCC Quant Ranking